Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019, and the outbreak rapidly evolved into the current coronavirus disease pandemic. SARS-CoV-2 is a respiratory virus that causes symptoms similar to those caused by influenza A and B viruses. On July 2, 2020, the US Food and Drug Administration granted emergency use authorization for in vitro diagnostic use of the Influenza SARS-CoV-2 Multiplex Assay. This assay detects influenza A virus at 10 2.0 , influenza B virus at 10 2.2 , and SARS-CoV-2 at 10 0.3 50% tissue culture or egg infectious dose, or as few as 5 RNA copies/reaction. The simultaneous detection and differentiation of these 3 major pathogens increases overall testing capacity, conserves resources, identifies co-infections, and enables efficient surveillance of influenza viruses and SARS-CoV-2.
【저자키워드】 COVID-19, 2019 novel coronavirus disease, coronavirus disease, severe acute respiratory syndrome coronavirus 2, viruses, respiratory infections, zoonoses, SARS-CoV-2, Coronaviruses, Influenza, influenza A, real-time RT-PCR, multiplex, acute respiratory infections, Flu SC2 Multiplex, influenza B, 【초록키워드】 coronavirus disease, severe acute respiratory syndrome coronavirus 2, coronavirus, pandemic, Influenza, influenza A virus, diagnostic, Influenza virus, Symptom, drug, in vitro, severe acute respiratory syndrome Coronavirus, virus, influenza A, Emergency use authorization, RNA, Multiplex assay, Culture, pathogen, Surveillance, respiratory virus, outbreak, influenza viruses, Pathogens, respiratory, differentiation, influenza B, food, infectious dose, tissue culture, influenza B virus, US Food and Drug Administration, acute respiratory syndrome, acute respiratory syndrome coronavirus, tissue, reaction, resources, identify, detect, caused, increase, cause, 【제목키워드】 coronavirus, influenza A virus, coronavirus 2, PCR, respiratory,